CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies

Authors: Hong Qin, Zhenyuan Dong, Xiuli Wang, Wesley A. Cheng, Feng Wen, Weili Xue, Han Sun, Miriam Walter, Guowei Wei, D. Lynne Smith, Xiuhua Sun, Fan Fei, Jianming Xie, Theano I. Panagopoulou, Chun-Wei Chen, Joo Y. Song, Ibrahim Aldoss, Clarisse Kayembe, Luisa Sarno, Markus Müschen, Giorgio G. Inghirami, Stephen J. Forman, Larry W. Kwak

Published: 2019-09-25

DOI: 10.1126/scitranslmed.aaw9414

Source: Full article

---

Abstract

BAFF receptor is a target for CAR T cell therapy of B cell malignancies, circumventing issues with CD19 antigen loss in tumors.